# Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Source: https://onco.cc/trials/nct06445062/  
OnCo record `nct06445062` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Daraxonrasib, Bevacizumab, Cetuximab in colorectal cancer and pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors is a phase 1/2 interventional study registered as NCT06445062 by Revolution Medicines, Inc., with 1130 participants planned, started 2024-05-24 and due to reach its primary completion in 2027-05-15. Interventions recorded: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab. Conditions listed: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06445062
- Phase: 1/2
- Setting: A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 1130

## Sources

- ClinicalTrials.gov NCT06445062: https://clinicaltrials.gov/study/NCT06445062

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06445062.json